Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Clascoterone and LGD-4033 Interaction: Monitor | Peptide Database

Compound Profiles Clascoterone Topical Androgen Receptor Inhibitor | Acne & Hair Loss Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Clascoterone

Topical Androgen Receptor Inhibitor | Acne & Hair Loss

Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia).

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Clascoterone with LGD-4033?

Yes, but with caution. Both Clascoterone and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. Regular monitoring is advised.

Is Clascoterone and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, teratogenic. Monitor accordingly.

What are the interactions between Clascoterone and LGD-4033?

Both Clascoterone and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Clascoterone and LGD-4033?

Clascoterone has a half-life of Short topical (local action; rapidly metabolized to cortexolone) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Phenylpiracetam enhances memory consolidation and retrieval through AMPA receptor modulation and increased dopaminergic signaling. Clinical studies in patients with cognitive impairment from organic brain disease and cerebrovascular conditions have shown statistically significant improvements in memory test scores. The dopaminergic and noradrenergic activity of phenylpiracetam provides a clean stimulant effect that enhances sustained attention, task motivation, and mental stamina. This distinguishes it from piracetam and most other racetams, which lack meaningful stimulant properties. Phenylpiracetam improves physical endurance, reduces perception of effort, and enhances exercise tolerance. These effects were significant enough to earn it a place on the WADA prohibited substances list. Athletes have reported improved stamina and recovery during competition. Phenylpiracetam was approved in Russia for asthenia and chronic fatigue states of various origins. Clinical trials demonstrated improvements in subjective energy, motivation, and capacity for sustained mental and physical work in patients with post-infectious, cerebrovascular, and post-traumatic asthenia. Approved for cognitive deficits associated with cerebrovascular disease. Patients showed improvements in memory, attention, and overall cognitive functioning, along with reductions in depression and anxiety. Phenylpiracetam has demonstrated anticonvulsant properties in preclinical models and was included in the Russian clinical indication for adjunctive treatment of convulsive conditions. Developed for Soviet cosmonauts to withstand extreme cold. Animal studies confirm that phenylpiracetam significantly increases resistance to hypothermia. This property is unique among the racetam family and has potential applications for military, aerospace, and extreme sports contexts. The dopaminergic activity of phenylpiracetam provides mood-elevating effects that may benefit individuals with depression, particularly anhedonic subtypes. This remains investigational, with supporting evidence primarily from clinical observations and the known pharmacological profile rather than large-scale controlled trials.

Source: peptide-db.com ↗

Community Research

Join others researching Nandrolone — share findings, ask questions, and learn from real experiences Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP). Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1. A key distinguishing feature of nandrolone is its interaction with 5-alpha reductase: unlike testosterone, which is converted to the more potent androgen dihydrotestosterone (DHT), nandrolone is reduced to dihydronandrolone (DHN), a weaker androgen. This results in lower androgenic activity in tissues rich in 5-alpha reductase (skin, prostate, hair follicles). Nandrolone also stimulates collagen synthesis and bone mineral content through direct effects on osteoblasts and fibroblasts, contributing to its well-documented benefits for joint and connective tissue health. It exhibits moderate progestogenic activity, binding to the progesterone receptor at approximately 20% the affinity of progesterone, which can influence prolactin levels and contribute to progesterone-related side effects. Nandrolone aromatizes to estradiol at roughly 20% the rate of testosterone, resulting in lower but not absent estrogenic activity.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Rosuvastatin is administered exclusively via the oral route as film-coated tablets. Unlike some statins that must be taken in the evening due to short half-lives, rosuvastatin's long 19-hour half-life allows dosing at any time of day without loss of efficacy. It can be taken with or without food, though food modestly reduces the rate (but not extent) of absorption. Bioavailability is approximately 20%, with the liver being the primary site of action. Rosuvastatin undergoes minimal hepatic metabolism via CYP2C9 (with minor CYP2C19 involvement), resulting in fewer drug-drug interactions compared to statins metabolized by CYP3A4. On-Cycle Lipid Management (AAS Use) 5-10 mg/day Once daily Oral Aggressive Lipid Lowering 10-20 mg/day Standard Hyperlipidemia (Non-AAS) 5-20 mg/day

Source: peptide-db.com ↗
Side effects

Common Side Effects

Headache (16% incidence, most common side effect) Flushing / warmth (10%, due to systemic vasodilation) Dyspepsia / indigestion (7%) Nasal congestion / rhinitis (4%) Visual disturbances -- blue-tinged vision, increased brightness perception, blurred vision (3%, due to PDE6 cross-reactivity in retinal photoreceptors) Dizziness (2%) Diarrhea (3%) Rash (2%)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →